Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Knature Biopharm Files Hong Kong IPO Backed by NAD+ Mitochondrial Platform

Fineline Cube Jan 26, 2026
Company Deals

GenEditBio Partners with uBriGene on LNP Ex Vivo Tech for Cell Therapy Manufacturing

Fineline Cube Jan 26, 2026
Company Deals

Merck Abandons $32 Billion Revolution Medicines Acquisition Over Price Dispute

Fineline Cube Jan 26, 2026
Company Deals

Dizal Pharmaceutical Files for Hong Kong IPO, Backed by AstraZeneca and First‑in‑Class Oncology Assets

Fineline Cube Jan 26, 2026
Company Deals

HealZen Inks Global DAC Partnership, Second TPD Deal Following J&J Alliance

Fineline Cube Jan 26, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Drug

Ascletis Doses First Patient in US Phase II Diabetes Study for Oral GLP‑1 ASC30

Fineline Cube Jan 26, 2026
Company Drug

Sanofi’s Amlitelimab Hits Phase III Goals in Atopic Dermatitis, Targets Q4W/Q12W Dosing Edge

Fineline Cube Jan 26, 2026
Company Deals

Nona Biosciences Partners with Kodiak Sciences to Discover Multi-Target Ophthalmic Antibodies

Fineline Cube Dec 10, 2024

Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has joined forces with...

Company Drug

Eisai’s Urece (Dotinurad) Approved by China’s NMPA for Gout Treatment with Hyperuricemia

Fineline Cube Dec 10, 2024

Eisai’s (TYO: 4523) China unit has announced that it has received marketing approval from the...

Company Drug

Daiichi Sankyo and AstraZeneca’s Datopotamab Deruxtecan Earns FDA Breakthrough Therapy Designation

Fineline Cube Dec 10, 2024

Partners Daiichi Sankyo (TYO: 4568) and AstraZeneca (AZ, NASDAQ: AZN) have jointly announced that their...

Company Deals

Shanghai Pharmaceuticals and Sichuan Kelun-Biotech Partner to Expand Sacituzumab Tirumotecan Market Access

Fineline Cube Dec 10, 2024

Shanghai Pharmaceuticals (SHA: 601607; SPH) has entered into a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical...

Company Drug

China Medical System’s Methylthioninium Tablets Receive First Prescriptions for Colonoscopy Use

Fineline Cube Dec 10, 2024

China Medical System Holdings (CMS; HKG: 0867) has announced that the first prescriptions have been...

Company Drug

Dizal Pharmaceutical Unveils Promising Data on DZD8586 for B-NHL at ASH Annual Meeting

Fineline Cube Dec 10, 2024

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has presented new data from a pooled safety...

Company Drug

AbbVie’s Tavapadon Shows Positive Results in Phase III TEMPO-2 Study for Parkinson’s Disease

Fineline Cube Dec 10, 2024

US-based pharmaceutical company AbbVie (NYSE: ABBV) has revealed positive top-line results from the pivotal Phase...

Company Drug

Eli Lilly’s Jaypirca Demonstrates Superiority in BRUIN CLL-321 Study for CLL/SLL Treatment

Fineline Cube Dec 10, 2024

US pharmaceutical major Eli Lilly and Company (NYSE: LLY) unveiled the latest data from the...

Policy / Regulatory

CDE Releases 89th Batch of Reference Preparations for Generic Quality Consistency

Fineline Cube Dec 10, 2024

The Center for Drug Evaluation (CDE) in China has announced the selection of the 89th...

Company Deals

Jiangsu Hengrui Pharmaceuticals Plans Secondary Listing on Hong Kong Stock Exchange

Fineline Cube Dec 10, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has confirmed reports regarding its intention to make...

Company Drug

Keymed Biosciences Presents CM336 Data for Relapsed Multiple Myeloma at ASH Annual Meeting

Fineline Cube Dec 10, 2024

China-based Keymed Biosciences Inc., (HKG: 2162) has announced the presentation of the latest data from...

Company Drug

Antengene’s Xpovio Showcases Positive Results in Phase III BENCH and Phase I/II TOUCH Studies at ASH 2024

Fineline Cube Dec 10, 2024

China-based Antengene Corporation Limited (Antengene, HKG: 6996) announced the presentation of the latest results from...

Company Drug

Lee’s Pharmaceutical Receives NMPA Approval for Generic Glaucoma Treatments

Fineline Cube Dec 10, 2024

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary, Zhaoke Ophthalmology Ltd (HKG: 6622), has announced...

Policy / Regulatory

NMPA Proposes Draft for Simplified Registration of Traditional Chinese Medicines from Hong Kong and Macao

Fineline Cube Dec 10, 2024

The National Medical Products Administration (NMPA) has issued the “Notification on Simplifying the Registration and...

Policy / Regulatory

China’s NHSA and NHC Issue Guidelines to Enhance Volume-based Procurement Mechanism

Fineline Cube Dec 10, 2024

The National Healthcare Security Administration (NHSA) and National Health Commission (NHC) of China have released...

Company Drug

CSPC Pharmaceutical Group’s SYHX2011 for Metastatic Breast Cancer Accepted for NMPA Review

Fineline Cube Dec 10, 2024

China-based CSPC Pharmaceutical Group Co., Ltd. (HKG: 1093) has announced that the National Medical Products...

Company Drug

GSK’s Nucala Receives FDA Review for COPD Indication Based on MATINEE Study Data

Fineline Cube Dec 10, 2024

UK-based pharmaceutical giant GSK (NYSE: GSK) has announced that the US Food and Drug Administration...

Company Deals

Hantech Medical Device Co., Ltd Acquires BD’s Villamarzana Factory to Expand Manufacturing

Fineline Cube Dec 10, 2024

China-based Hantech Medical Device Co., Ltd, a Contract Development Manufacturing Organization (CDMO) specializing in medical...

Company Deals

Precision Biotech and T&L Biotechnology Form Partnership to Advance Cell and Gene Therapies

Fineline Cube Dec 10, 2024

China-based Precision Biotech has announced a strategic partnership with compatriot firm T&L Biotechnology Co., Ltd....

Company Medical Device

MicroPort Scientific Corp. Launches FireFalcon Balloon for Coronary Interventions with NMPA Approval

Fineline Cube Dec 10, 2024

Shanghai-based medical device giant MicroPort Scientific Corp., (HKG: 0853) has announced that it has received...

Posts pagination

1 … 197 198 199 … 614

Recent updates

  • Ascletis Doses First Patient in US Phase II Diabetes Study for Oral GLP‑1 ASC30
  • Knature Biopharm Files Hong Kong IPO Backed by NAD+ Mitochondrial Platform
  • Sanofi’s Amlitelimab Hits Phase III Goals in Atopic Dermatitis, Targets Q4W/Q12W Dosing Edge
  • MicroPort Endovascular’s Talos Stent Graft Secures EU CE MDR Certification
  • Huahui Health’s Libevitug Wins NMPA Approval as World’s First HDV Antibody Therapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Ascletis Doses First Patient in US Phase II Diabetes Study for Oral GLP‑1 ASC30

Company Deals

Knature Biopharm Files Hong Kong IPO Backed by NAD+ Mitochondrial Platform

Company Drug

Sanofi’s Amlitelimab Hits Phase III Goals in Atopic Dermatitis, Targets Q4W/Q12W Dosing Edge

Medical Device

MicroPort Endovascular’s Talos Stent Graft Secures EU CE MDR Certification

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.